Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

33.45 (USD) • At close July 29, 2025
Bedrijfsnaam Supernus Pharmaceuticals, Inc.
Symbool SUPN
Munteenheid USD
Prijs 33.45
Beurswaarde 1,872,852,120
Dividendpercentage 0%
52-weken bereik 27.05 - 40.28
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. Jack A. Khattar
Website https://www.supernus.com

An error occurred while fetching data.

Over Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis

Vergelijkbare Aandelen

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

11.19 USD

Vaxcyte, Inc. logo

Vaxcyte, Inc.

PCVX

34.68 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

30.87 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

15.53 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

152.08 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.54 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

41.23 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

107.89 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

131.58 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)